Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 2372135, 8 pages
https://doi.org/10.1155/2017/2372135
Research Article

Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma

1Clinical Outcomes Solutions, Tucson, AZ, USA
2Purple Squirrel Economics, New York, NY, USA
3Eisai Ltd., Hertfordshire, UK
4UT Southwestern Medical Center, Dallas, TX, USA
5Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

Correspondence should be addressed to Stacie Hudgens; moc.snoitulostuonilc@snegduh.eicats

Received 16 December 2016; Accepted 13 March 2017; Published 23 April 2017

Academic Editor: Peter C. Ferguson

Copyright © 2017 Stacie Hudgens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Wibmer, A. Leithner, N. Zielonke, M. Sperl, and R. Windhager, “Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review,” Annals of Oncology, vol. 21, no. 5, pp. 1106–1111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Howlader, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2012, National Cancer Institute, Bethesda, Md, USA, 2015.
  3. Cancer Facts & Figures 2016, American Cancer Society, 2016.
  4. A. J. Jacobs, R. Michels, J. Stein, and A. S. Levin, “Improvement in overall survival from extremity soft tissue sarcoma over twenty years,” Sarcoma, vol. 2015, Article ID 279601, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. National Comprehensive Cancer Network, Practice Guidelines in Oncology, 2016.
  6. M. Eriksson, “Histology-driven chemotherapy of soft-tissue sarcoma,” Annals of Oncology, vol. 21, supplement 7, pp. vii270–vii276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Gronchi, S. Ferrari, V. Quagliuolo et al., “Full-dose neoadjuvant anthracycline+ ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: interim analysis of a prospective randomized trial,” Annals of Oncology, vol. 27, supplement 6, article LBA6, 2016. View at Google Scholar
  8. R. Petrioli, A. Coratti, P. Correale et al., “Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma,” American Journal of Clinical Oncology, vol. 25, no. 5, pp. 468–473, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Schoffski, I. L. Ray-Coquard, A. Cioffi et al., “Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052),” Journal of Clinical Oncology, vol. 28, no. 15, pp. 10031–10031, 2010. View at Publisher · View at Google Scholar
  10. D. Schreiber, R. S. Bell, J. S. Wunder et al., “Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma,” Quality of Life Research, vol. 15, no. 9, pp. 1439–1446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Reichardt, M. Leahy, X. Garcia del Muro et al., “Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) study,” Sarcoma, vol. 2012, Article ID 740279, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. King, “The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30,” Quality of Life Research, vol. 5, no. 6, pp. 555–567, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Hudgens, A. Forsythe, I. Kontoudis, D. D'Adamo, A. Bird, and H. Gelderblom, “Evaluation of quality of life at progression in patients with soft tissue sarcoma,” Journal of Clinical Oncology, vol. 34, abstract 11015, 2016. View at Google Scholar